Methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate

We are Methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate CAS:334952-07-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  Methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate
CAS.NO: 334952-07-7
Synonyms:
Methyl 2-(4-((6-fluoro-2-quinoxalinyl)oxy)phenoxy)propanoate
(4-Methoxycarbonyl-2-nitro-phenyl)-essigsaeure-methylester
Propanoic acid,2-(4-((6-fluoro-2-quinoxalinyl)oxy)phenoxy)-,methyl ester
methyl 2-[4-(6-fluoro-2-quinoxalyloxy)phenoxy]propionate
methyl 2-[4-(methyloxycarbonyl)-2-nitrophenyl]-acetate
(4-methoxycarbonyl-2-nitro-phenyl)-acetic acid methyl ester
methyl 4-methoxycarbonylmethyl-3-nitro-benzoate
4-methoxycarbonylmethyl-3-nitrobenzoic acid methyl ester

Molecular Formula:C11H11NO6
Molecular Weight: 253.20800

Physical and Chemical Properties:
Density: 1.3±0.1 g/cm3
Boiling point:369.6±32.0 °C at 760 mmHg
Melting point: /
Flash point: 162.6±27.1 °C
Refractive index: 1.543

Specification:
Appearance:/
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Nintedanib esylate CAS:656247-18-6
Intermediates of Nintedanib CAS:656247-17-5

Related News: However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period.1-Benzhydrylazetidin-3-One CAS:40320-60-3 ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.533-68-6 The company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.2,4-Difluorobenzyl Chloride CAS:452-07-3 Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.